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Inflammatory, regulatory, and autophagy
co-expression modules and hub genes
underlie the peripheral immune response
to human intracerebral hemorrhage
Marc Durocher1, Bradley P. Ander1, Glen Jickling1, Farah Hamade1, Heather Hull1, Bodie Knepp1, Da Zhi Liu1,
Xinhua Zhan1, Anh Tran1, Xiyuan Cheng1, Kwan Ng1, Alan Yee1, Frank R. Sharp1 and Boryana Stamova1,2*
Abstract
Background: Intracerebral hemorrhage (ICH) has a high morbidity and mortality. The peripheral immune system
and cross-talk between peripheral blood and brain have been implicated in the ICH immune response. Thus, we
delineated the gene networks associated with human ICH in the peripheral blood transcriptome. We also compared
the differentially expressed genes in blood following ICH to a prior human study of perihematomal brain tissue.
Methods: We performed peripheral blood whole-transcriptome analysis of ICH and matched vascular risk factor
control subjects (n = 66). Gene co-expression network analysis identified groups of co-expressed genes (modules)
associated with ICH and their most interconnected genes (hubs). Mixed-effects regression identified differentially
expressed genes in ICH compared to controls.
Results: Of seven ICH-associated modules, six were enriched with cell-specific genes: one neutrophil module, one
neutrophil plus monocyte module, one T cell module, one Natural Killer cell module, and two erythroblast modules.
The neutrophil/monocyte modules were enriched in inflammatory/immune pathways; the T cell module in T cell
receptor signaling genes; and the Natural Killer cell module in genes regulating alternative splicing, epigenetic, and
post-translational modifications. One erythroblast module was enriched in autophagy pathways implicated in
experimental ICH, and NRF2 signaling implicated in hematoma clearance. Many hub genes or module
members, such as IARS, mTOR, S1PR1, LCK, FYN, SKAP1, ITK, AMBRA1, NLRC4, IL6R, IL17RA, GAB2, MXD1,
PIK3CD, NUMB, MAPK14, DDX24, EVL, TDP1, ATG3, WDFY3, GSK3B, STAT3, STX3, CSF3R, PIP4K2A, ANXA3,
DGAT2, LRP10, FLOT2, ANK1, CR1, SLC4A1, and DYSF, have been implicated in neuroinflammation, cell death,
transcriptional regulation, and some as experimental ICH therapeutic targets. Gene-level analysis revealed 1225
genes (FDR p < 0.05, fold-change > |1.2|) have altered expression in ICH in peripheral blood. There was significant
overlap of the 1225 genes with dysregulated genes in human perihematomal brain tissue (p = 7 × 10−3). Overlapping
genes were enriched for neutrophil-specific genes (p = 6.4 × 10−08) involved in interleukin, neuroinflammation,
apoptosis, and PPAR signaling.
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Conclusions: This study delineates key processes underlying ICH pathophysiology, complements experimental ICH
findings, and the hub genes significantly expand the list of novel ICH therapeutic targets. The overlap between blood
and brain gene responses underscores the importance of examining blood-brain interactions in human ICH.
Keywords: Intracerebral hemorrhage, ICH, NRF2, Autophagy, Hematoma, Hematoma clearance, Src kinase inhibitors,
Gene expression, Co-expression networks, Gene networks
Introduction
Approximately 795,000 strokes occur in the USA each
year [1]. Stroke remains a leading cause of death and
disability [2, 3]. Although primary non-traumatic intra-
cerebral hemorrhage (ICH) only accounts for 10–15% of
strokes [1, 4], its mortality rate of 59% at 1 year [4] is
much higher than that for ischemic stroke (IS) (14%) [5].
Many pre-clinical and a few clinical studies implicate
neuroinflammation as contributing to neurological injury
produced by ICH [3, 6, 7]. Following ICH, a complex cas-
cade of local and systemic immune responses occurs lead-
ing to blood-brain barrier disruption, cerebral edema, and
cell damage/death followed by hematoma removal and
brain repair [7–11]. Since there is communication between
the peripheral immune system and the central nervous sys-
tem through afferent and efferent trafficking of cells and
molecules, the peripheral immune system is a key driver of
damage and repair following ICH [7, 12, 13]. Peripheral
leukocytic infiltration into the brain is seen early following
ICH [7]. This involves chemokines, cytokines, matrix me-
talloproteinases (MMPs), and interactions between circulat-
ing leukocytes and vascular endothelial cells, with different
cell types employing common as well as unique pathways
[14]. Thus, it is important to study both the local and sys-
temic immune response to human ICH.
We examined the systemic peripheral immune response
to human ICH and how it compares to the local human
perihematomal brain tissue response. We investigated the
peripheral blood gene co-expression networks and their
most interconnected genes (hubs) following ICH, identi-
fied differential gene-level RNA expression and the poten-
tially affected pathways, and compared the peripheral
blood response to the one in previously published human
peri-hematoma ICH brain [15]. The hub genes we identi-
fied have been implicated as major regulators of the im-
mune response including the inflammasome, autophagy,
and transcriptional and epigenetic regulation. Some of the
hub genes have also been successfully tested in animal
ICH models. Notably, there was a significant overlap be-
tween genes differentially expressed in this human ICH
peripheral blood study compared to a prior human study
of perihematomal brain tissue [15]. These findings will
further our understanding of the biological processes oc-
curring following ICH, as well as provide human data con-
firming targets that have been tested or will be tested in
animal ICH models. The findings also highlight candidate
genes that influence major processes underlying the re-
sponse to ICH and parallel responding genes/pathways in
blood and brain, underscoring the importance of further
studies of the peripheral blood-brain immune
communication.
Materials and methods
Study subjects
Sixty-six male (M) and female (F) subjects with intrace-
rebral hemorrhage (ICH, n = 33, 24M/9F) and vascular
risk factor (VRF)-matched control subjects (CTRL, n =
33, 24M/9F) were recruited from the Universities of
California at Davis and San Francisco as well as the Uni-
versity of Alberta, Canada. Procedures were approved by
the IRBs at participating universities and written in-
formed consent was obtained from participants or their
proxy. ICH was diagnosed by board-certified neurolo-
gists based upon histories, exams, and magnetic reson-
ance imaging (MRI) and/or computed tomographic (CT)
brain scan [16]. Subjects were matched for age, race, sex,
and VRFs, which included hypertension, diabetes melli-
tus, hyperlipidemia, and smoking status. Exclusion cri-
teria were previous stroke (for CTRLs) and ischemic
stroke with hemorrhagic transformation.
Blood collection, RNA isolation
Blood was collected in PAXgene tubes and RNA isolated
as previously described [17, 18]. There was a single
blood draw per subject. Time after symptom onset for
ICH varied from 4.2 to 124.3 h.
Arrays and processing
RNA was processed on the GeneChip® Human Tran-
scriptome Array (HTA) 2.0 (Affymetrix, Santa Clara,
CA) which examines the coding and non-coding tran-
scriptome. Raw expression values for each gene were
saved in Affymetrix.CEL and Affymetrix.DAT files. Using
Affymetrix Power Tools (APT), the. CEL transformer
applied GC correction (GCCN) and single space trans-
formation (SST) to the HTA.CEL files. GCCN-SST
transformations were conducted through a command
line using APT 1.18.0 in “batch” mode. GCCN-SST
transformed .CEL files were uploaded into Partek Flow
software (Partek Inc., St. Louis, MO) and probe sets
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mapped to the Human Genome hg19 using the STAR
2.4.1d aligner. Nominal read coverage depth was defined
as 30 million and default mapping parameters were
used. RPKM normalization was performed.
Weighted gene co-expression network construction and
analysis
The 56,638 genes (mRNA and ncRNA) present in ICH
and CTRL data were filtered by removing genes with a
maximum expression across all samples of < 5, leaving
29,513 genes. Then, genes with expression < 3 in greater
than 50% of the male and female samples across all
groups were removed, leaving 21,175 genes. This was
done to remove potential outliers, reduce noise, decrease
sex bias due to an uneven number of males and females
in the data, and focus analyses on the most robust corre-
lations. Data were then imported into R and the function
goodSamplesGenes within the WGCNA package used to
identify any missing values or zero-variance genes to be
removed from the sample. The CTRL and ICH data
were then processed in R using WGCNA [19].
WGCNA identified Pearson correlations throughout
the data to develop modules of co-expressed genes. An
approximate scale-free topology was depicted by the
data, as is expected of gene co-expression networks [20].
To maximize strong correlations between genes, we
assigned a soft-thresholding power β = 8 since it was the
lowest β with the highest R2 value that passed the 0.8
threshold (Additional file 1: Figure S1). Due to the large
number of genes being processed, we set the minimum
module size to 100 genes. Rather than using a static
cut-off during module construction, we utilized the
cutreeDynamic function to form modules because of its
ability to identify nested modules within complex den-
drograms [21]. Additional parameters within cutreeDy-
namic included method = “tree” and deepSplit = FALSE.
To focus on genes of likely greatest importance in ICH,
we identified those with the top 5% highest membership
to their respective module [22]. These hub genes are
highly interconnected within the module and their inter-
connectivity was quantified by kIN—the gene’s intra-
modular connectivity [23]. Significant modules with
respect to diagnosis (ICH, CTRL) were extracted (p(Dx)
< 0.05) for additional processing.
Differential gene expression
Differentially expressed genes were derived using Partek
Genomics Suite 7.17 software (Partek Inc., St. Louis,
MO) on the complete post-filtered dataset of 21,175
genes. A three-way ANCOVA model with REML (re-
stricted maximum likelihood) and the factors diagnosis,
scan date, sex, age, time, and an interaction between
diagnosis and sex was used. Genes passing a FDR
(false-discovery rate) p value < 0.05 and a fold change
(FC) > |1.2| for ICH vs CTRL were considered
significant.
Cell-specific gene involvement
To identify modules of co-expressed genes enriched with
blood cell type-specific genes, we overlapped the gene
list of each module with lists of blood cell type-specific
genes [24, 25]. We calculated significant overlaps of
genes using hypergeometric probability testing with the
R function phyper. Those with a p < 0.05 were deemed
significant.
Pathway and gene ontology analyses
Hub genes and modules significant for diagnosis were
further analyzed with ingenuity pathway analysis (IPA)
[26] and the DAVID Bioinformatics Database (DAVID
6.8) [27]. Module genes were input into IPA to map
them to molecular functions, associated diseases, and ca-
nonical pathways [28] using Fisher’s exact test p < 0.05
and a multiple-comparison correction via the Benjamini-
Hochberg procedure (adjusted p < 0.05). The same lists
of module genes were input into DAVID for gene ontol-
ogy (GO) analysis (EASE adjusted Fisher’s exact test p <
0.05).
Network visualization and hub gene identification
The R function within WGCNA visantPrepOverall gen-
erated a list of intramodular gene connections that were
imported into VisANT to visualize the networks [29,
30]. To better capture hub gene connectivity, parameters
modified within the visantPrepOverall function were
numint = 10,000 and signed = FALSE. After importing
the data into VisANT, the minimum weight cutoff was
adjusted to display a visually distinguishable number of
connections. The lengths and colors of the edges (con-
nections) in the images are arbitrary. Networks were cre-
ated with VisANT for modules deemed significant with
p(Dx) < 0.05 and for significant hub gene networks
within them.
Results
Demographic and clinical characteristics
Subjects’ demographic and clinical characteristics are
listed in Additional file 2: Table S1 [18]. There were no
significant differences in hypertension, diabetes mellitus,
hyperlipidemia, or smoking for ICH compared to CTRL
subjects. Time since ICH to blood draw was 57.3 ±
30.6 h (± standard deviation). The mean age of ICH sub-
jects was 62 ± 14.3 years (± standard deviation) and was
not significantly different from 63.5 ± 13.1 years for
CTRL.
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WGCNA: ICH and CTRL analysis
Module assignments
Analysis of the 66 samples (33 CTRL and 33 ICH) for
21,175 genes identified 41 modules of co-expressed
genes. Modules ranged in size from 2416 (turquoise) to
114 genes (lightsteelblue1). A gene dendrogram and
their modules are shown in Fig. 1a. A dendrogram of the
module eigengenes (representative of the overall gene
expression within that module) is shown in Fig. 1b.
Genes and their module assignments are listed.
in Additional file 2: Table S2. Of the 41 modules, 7
showed a significant difference between ICH and CTRL
groups with p(Dx) < 0.05 (cyan, darkolive green, green-
yellow, magenta, red, sienna3, and tan) (marked with as-
terisks in Fig. 1a and colored in module-corresponding
colors in Fig. 1b).
Cell type involvement
We then compared the genes in the ICH-associated
modules (p(Dx) < 0.05) to genes reported to be expressed
in normal human erythroblasts, megakaryocytes, B cells,
cytotoxic and helper T cells, natural killer cells, granulo-
cytes, or monocytes [24, 25]. There was significant over-
lap/enrichment in six of the seven ICH modules
(Fig. 1a). Cyan and sienna3 were enriched for
erythroblast-specific genes (p = 4.9 × 10−10 and p < 1 ×
10−16, respectively); tan—with CD66b+/neutrophil-speci-
fic genes (p < 1 × 10−16); and greenyellow—with CD14+/
monocyte and CD66b+/neutrophil-specific genes (p =
2.9 × 10−06 and p < 1 × 10−16, respectively). Magenta was
enriched with genes selectively expressed in T cells (p <
1 × 10−16), and red with CD56+/natural killer
cell-specific genes (p = 1.8 × 10−2). Lists of these genes
and their modules are in Additional file 2: Table S3.
Central intramodular hub genes
Hub genes may be important targets for treating ICH. A
list of hub genes for each module is in Additional file 2:
Table S4 and the canonical pathways for those hub genes
are listed in Additional file 2: Table S5. The VisANT net-
works of the ICH-associated modules, including their
hub genes and the biological processes that are overrep-
resented in each module are depicted in Figs. 2, 3, and 4.
Figures 2a, c, 3a, c, and 4a, c, d show the networks of
the seven ICH diagnosis-significant modules, where the
enlarged, labeled, and colored (non-gray) nodes are the
module’s hub genes. Not all genes and connections are
displayed since inclusion of too many generated an in-
comprehensible image.
The most statistically significant hub genes included
isoleucyl-TRNA synthetase (IARS) (Fig. 3a; Additional file 1:
Figure S2); sphingosine-1 phosphate receptor 1 (S1PR1)
(Additional file 1: Figure S3); T cell receptor alpha joining
36 (TRAJ36) (Fig. 3a); proto-oncogene, Src family tyrosine
kinase (LCK) (Fig. 5); IL2 inducible T cell kinase (ITK)
(Additional file 1: Figure S4); mediator complex subunit 1
(MED1), mediator complex subunit 14 (MED14), small nu-
clear ribonucleoprotein U5 subunit 200 (SNRNP200)
(Fig. 6), mechanistic target of rapamycin kinase (mTOR),
autophagy nd beclin 1 regulator 1 (AMBRA1) (mTOR and
Fig. 1 A dendrogram of the genes and their module assignments (a); a dendrogram of only the module eigengenes (representative of the
overall gene expression within that module) (b). The significant modules in respect to Dx (cyan, darkolivegreen, greenyellow, magenta, red,
sienna3, and tan) are marked with asterisks in (a) and colored in module-corresponding colors in (b). Dx-specific modules with significant
overlap/enrichment with cell-specific genes are labeled in (a) with the specific cell type, and the hypergeometric probability p value of overlap
between the module’s gene list and the cell type-specific gene list from Watkins et al. [31] and T cell-specific genes from Additional file 2: Table
S1 from Chtanova et al. [32] is presented
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AMBRA1 networks) (Additional file 1: Figures S5 and S6);
NLR family CARD domain containing 4 (NLRC4), WD re-
peat and FYVE domain containing 3 (WDFY3), microRNA
3614 (miR3614) (Additional file 1: Figures S7, S8, and S9);
autophagy related 3 (ATG3) (Additional file 1: Figure S10);
solute carrier family 4 member 1 (Diego blood group)
(SLC4A1), ankyrin 1 (ANK1) (Additional file 1: Figures S11
and S12); phosphatidylinositol-5-phosphate 4-kinase type 2
alpha (PIP4K2A) (Additional file 1: Figure S13); colony
stimulating factor 3 receptor (CSF3R) (Additional file 1:
Figure S14); and signal transducer and activator of
transcription 3 (STAT3) (Fig. 7). The p values for diagnosis
for the hub genes in all modules are in Additional file 2:
Table S6a.
There were two non-coding RNA hub genes:
SNRNP200 (Fig. 6) and microRNA miR3614 (Additional
file 1: Figure S9). Of the modules with a significant asso-
ciation to ICH diagnosis, DarkOliveGreen (the only
module not associated with a specific cell type) was the
only module that also showed an association to the time
since stroke onset. The p values for time-since-event for
all modules are shown in Additional file 2: Table S6b.
Fig. 2 Greenyellow module. a VisANT Network of greenyellow (neutrophil- and monocyte- specific) module. The hub genes are colored in green-
yellow. Neutrophil-specific hub genes are listed below. b Overrepresented canonical pathways in greenyellow (IPA analysis, Benjamini-Hochberg (B-H)
corrected p < 0.05). X-axis: negative Log10-transformed p-value for significance for enrichment in specific IPA pathways. Pathways higher than the black
vertical line (-Log10(B-H p)) > 1.3 (which corresponds to p(B-H p) < 0.05) are significant. c, d Tan module. Hub genes are colored in tan
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The hub genes for each module differed by cell type
and function. Notably, 14 out of 31 of the hub genes in
the greenyellow module were neutrophil-specific
(Fig. 2a). More than half of the hub genes in the tan
module were neutrophil-specific (17 out of the 28)
(Fig. 2c). Six hub genes in magenta (Fig. 3a) were T cell
specific. Three hub genes in sienna3 (erythroblast mod-
ule) were erythroblast-specific (Fig. 4c). Table 1 shows
all hub genes in the ICH-significant modules; Table 2
shows three representative hub genes for each module
and their relevant functions.
Pathway analyses
A list of pathways associated with each module is in
Additional file 2: Table S7. Selected pathways in the
ICH-associated modules are shown in Figs. 2b, d, 3b, d,
and 4b. The greenyellow module (neutrophil/monocyte
module) included toll-like receptor (TLR), inflamma-
some, and PPAR signaling which are all involved in neu-
roinflammation (Fig. 2b). The tan module (neutrophil
module) included leukocyte extravasation signaling
(Additional file 1: Figure S15), several interleukin-signal-
ing pathways, T and B cell receptor signaling, apoptosis
pathways, NF-κB signaling, and PPAR signaling. Tan
module functions included renin-angiotensin and
endothelin-1-signaling related to vasoconstriction/vaso-
dilation; and coagulation pathways such as thrombin sig-
naling (Fig. 2d).
The magenta module was mainly associated with T cell
receptor signaling (Additional file 1: Figure S16) and
pathways involving T lymphocytes (Fig. 3b) (CD28 sig-
naling in T helper cells, iCOS-iCOSL signaling in T
helper cells, Th1 and Th2 pathways, calcium-induced T
lymphocyte apoptosis, PKCθ, and Nur77 signaling in T
Fig. 3 a, b VisANT network of magenta (T cell specific) module. The Hub genes are colored in magenta. T cell specific hub genes are listed
below. b Overrepresented canonical pathways in magenta (IPA analysis, B-H corrected p < 0.05). X-axis: negative Log10-transformed p value for
significance for enrichment in specific IPA pathways. Pathways higher than the black vertical line (-Log10(B-H p)) > 1.3 (which corresponds to p(B-
H p) < 0.05) are significant. c, d Red module. Hub genes are colored in red
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lymphocytes). The red module (natural killer cell mod-
ule) was overrepresented with genes involved in DNA
repair and cell cycle regulation (Fig. 3d). The cyan mod-
ule (erythroblast module) was associated with the
NRF2-mediated oxidative stress response, protein ubi-
quitination, and clathrin-mediated endocytosis, which
are all pathways implicated in hematoma clearance fol-
lowing ICH [31–33], as well as heme biosynthesis path-
ways (Fig. 4b).
The statistically significant processes (p < 0.05) using
gene ontology (DAVID functional annotation tool) are
shown in Additional file 2: Table S8. The top 3 in each
module are listed in Fig. 8. Some of the processes not
mentioned above included apoptosis and autophagy
(greenyellow), insulin receptor signaling (darkolive-
green), amino acid transport and Wnt signaling (si-
enna3), protein ubiquitination and macroautophagy and
mitophagy (cyan), mRNA splicing and protein sumoyla-
tion (red), and MAPKK and JAK-STAT signaling (tan).
Gene-level expression in blood compared to perihematomal
brain
Of the 21,175 genes examined in this study, 1225 showed
differential gene-level expression between ICH and CTRL
(FDR p < 0.05, FC > |1.2|; Additional file 2: Table S9a).
There were 63 hub genes (Table 1) from the 7 modules as-
sociated with ICH (Additional file 2: Table S9b). The most
significant pathways associated with the 1225 genes were
T and B cell receptor signaling, Th1 and Th2 activation,
neuroinflammation, and IL-1, -2, -6, -8, -10, and -12 sig-
naling (Additional file 2: Table S9c). The 1225 gene list
was enriched with genes associated with neutrophils (p <
1 × 10−16) and T cells (p = 1.9 × 10−3) (Additional file 2:
Table S9d). There was neutrophil enrichment in greenyel-
low and tan modules (p = 5.6 × 10−13 and p = 4.6 × 10−4,
respectively), and T cell enrichment in magenta (p = 3.1 ×
10−06) (Additional file 2: Table S9e).
By assessing gene-level expression in blood of ICH
subjects, we were able to compare our study to another
Fig. 4 a, b VisANT network of cyan (erythroblast-specific) module. The hub genes are colored in cyan. b Overrepresented canonical pathways in
cyan (IPA analysis, B-H corrected p < 0.05). X-axis: negative Log10-transformed p value for significance for enrichment in specific IPA pathways.
Pathways higher than the black vertical line (-Log10(B-H p)) > 1.3 (which corresponds to p(B-H p) < 0.05) are significant. c VisANT network of
sienna3 module. Hub genes are colored in sienna3. No IPA pathways passed B-H corrected p < 0.05. d VisANT network of darkolivegreen module.
Hub genes were colored in dark olive green. No IPA pathways passed B-H corrected p < 0.05
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that examined human perihematomal brain tissue [15].
Forty-six of our blood-derived differentially expressed
genes (DEGs) overlapped with the list of 534 DEGs from
the brain ICH study (p = 0.007; Additional file 2: Table
S9f ) (Fig. 9). The 46 DEGs showed enrichment for
neutrophil-specific genes (6.4 × 10−08; Additional file 2:
Table S9g). The 46 genes were involved in interleukin (1,
6, 8, and 10) signaling, neuroinflammation, apoptosis,
and PPAR signaling (Fisher’s Exact p < 0.05; Additional
file 2: Table S9h).
Discussion
Seven modules of co-expressed genes were associated
with ICH. Six were enriched in genes predominantly
expressed in specific cell types suggesting cell-specific
coordination of the peripheral immune response to ICH.
This confirms many experimental studies of a complex
immune response to ICH [7, 34]. The identified hub
genes are biologically relevant, involved in major path-
ways including immune, autophagy and transcriptional,
post-transcriptional, and epigenetic regulation and
hematoma clearance. A number of these pathways have
also been reported in experimental ICH studies [7, 34].
The data highlights the utility of systems-level ap-
proaches to studying human ICH.
Neutrophil and monocyte modules (greenyellow and tan
modules)
Neutrophils are among the first peripheral blood cell
type to infiltrate perihematomal brain and vessels and
the hematoma itself following ICH [35]. Neutrophils
contribute to blood-brain barrier (BBB) breakdown, che-
moattraction, activation of resident microglia, and brain
injury at early times following ICH [36]. Later, IL-27
shifts neutrophils from producing pro-inflammatory/
cytotoxic products to production of beneficial
iron-scavenging molecules like lactoferrin [37]. IL-27
and lactoferrin reduced edema, enhanced hematoma
clearance, and improved neurological outcomes in ex-
perimental ICH [37]. Peripheral monocytes also enter
the brain after ICH and eventually outnumber neutro-
phils [7]. They also appear to have adverse effects early,
but then contribute to tissue repair and hematoma
phagocytosis later after ICH [7].
Our data revealed two modules enriched in
neutrophil-specific genes and one of these was also
enriched in monocyte-specific genes. The greenyellow
(neutrophil and monocyte) module included IL-6, IL-8,
and IL-10 signaling; inflammasome pathway and phago-
some formation; toll-like receptor (TLR) signaling;
NF-kB and PPAR signaling; and processes involved in
Fig. 5 LCK network in the magenta module. Genes colored in magenta are hub genes. Note other Src kinases (like FYN and ITK) and Src kinase-
associated protein (SKAP1) are circled
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leukocyte extravasation through the BBB. Most of these
have been implicated in ICH [7]. For example, TLR sig-
naling affects ICH-induced brain injury and outcome
[38]. Serum levels of IL-6 and IL-10 increase following
ICH [39]. In addition, peroxisome proliferator-activated
receptors (PPARs), nuclear hormone receptors that
regulate immune/inflammatory responses, have been im-
plicated in ICH and PPARγ agonists improve experi-
mental ICH outcomes [40]. We previously documented
differential alternative splicing of PPARγ signaling mole-
cules in ICH [18], which further supports their role in
ICH.
Infiltrating neutrophils and monocytes release cyto-
kines, reactive oxygen species (ROS), and matrix me-
talloproteinases (MMPs), which affect ICH outcomes
[41, 42]. Indeed, the greenyellow module included
S100A8 (calcium and zinc-binding protein that regu-
lates the immune response); CCR2 (receptor for
monocyte chemoattractant protein-1 which mediates
monocyte chemotaxis with CCR2 + inflammatory
monocytes regulating hematoma clearance and func-
tional recovery following ICH) [7]; PLA2G4A
(PLA2G4A deficiency causes platelet dysfunction/
bleeding); CD36 (implicated in cerebral amyloid
angiopathy, one of the major causes of ICH) [43, 44];
F5 (coagulation factor V, a mutation in which causes
Factor V Leiden thrombophilia); and MMP9 (matrix
metalloproteinase 9 which causes BBB dysfunction
resulting in increased capillary permeability and brain
edema following ICH [7, 45]).
Of the 14 neutrophil-specific hub genes in the green-
yellow module, those with the highest connectivity in-
cluded MAPK14, WDFY3 (Additional file 1: Figure S8),
SULT1B1, DYSF, FLOT2, ANXA3, PYGL, and KLHL2.
Other greenyellow hubs were associated with
endothelin-1 signaling (PLBD1, MAPK14, CASP4),
which is implicated in cerebral vasospasm following sub-
arachnoid hemorrhage [46]. Serum endothelin-1 levels
are elevated in ischemic stroke [47] and ICH [48], and
endothelin-1 serum levels correlate with ICH hematoma
volumes [48].
Greenyellow hubs were also involved in chemokine
signaling (MAPK14, LIMK2), and eicosanoid signaling
(PLBD1, ALOX5), which promote inflammation and vas-
cular permeability [49, 50]. The NLRC4 hub (Additional
file 1: Figure S7) forms the NLRC4 inflammasome
Fig. 6 SNRNP200 network in the red module. Genes colored in red are hub genes. Yellow highlighted genes are transcription regulators
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[51, 52]. Inflammasomes, the innate immune system
complexes that regulate activation of caspase-1 and
IL-1 to induce inflammation in response to infection
and host damage molecules (DAMPs), have been im-
plicated in a variety of inflammatory processes [53]
including ICH [54]. In a mouse ICH model, another
inflammasome class, the NLRP3 inflammasome, amp-
lified the inflammatory response following ICH, sug-
gesting NLRP3 inflammasome inhibition may reduce
the ICH inflammatory response [54, 55]. Our data
suggest that NLRC4 type inflammasome response
may be important in human ICH, and the NLRC4
hub gene could be a therapeutic target.
There was one microRNA (miRNA) hub in the green-
yellow module, miR3614 (Additional file 1: Figure S9).
Though little is known about this miRNA, our data
show that the miR3614 hub is inter-connected with 40
genes (Additional file 1: Figure S9) enriched in IL-6 and
IL–10 signaling (MAPK14, IL1R2), granulocyte adhesion
and diapedesis (IL1R2, CXCL16), and phagosome forma-
tion (FCAR, CR1) (p < 0.05). The data suggest an im-
portant inflammatory/immune role for miR3614 in
human ICH.
The tan module included immune/inflammatory path-
ways such as leukocyte extravasation signaling (Add-
itional file 1: Figure S15), production of nitric oxide
(NO) and ROS, are all implicated in ICH [7]. Tan mod-
ule gene members included toll-like receptors TLR1,
TLR2, TLR4, and TLR6. The tan module also had 17
neutrophil-specific hub genes including IL6R, GAP2,
STAT3, and STX3.
The tan module was also enriched in Wnt/β-catenin
signaling which has been implicated in BBB maintenance
and breakdown and cell apoptosis [56–58]. Treatment
with an inhibitor of GSK-3β (glycogen synthase kinase 3
beta), a key molecule in the Wnt/β-catenin signaling
pathway, attenuated rtPA-induced hemorrhagic trans-
formation after acute ischemic stroke in rats [59]. Our
data revealed significant overrepresentation of Wnt/
β-catenin signaling pathway genes (11 genes), including
GSK-3β (Additional file 1: Figure S17), and support a
role for GSK-3β/Wnt/β-catenin signaling in human ICH.
The tan module was also associated with growth factor
signaling, including HGF, NGF, Neutrophin/TRK,
GM-CSF, IGF, FGF, renin-angiotensin, VEGF, and
JAK-STAT. ICH patients with high serum levels of
Fig. 7 STAT3 network in the tan module. Genes colored in tan are hub genes
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growth factors such as vascular endothelial growth fac-
tor (VEGF), granulocyte-colony stimulating factor
(G-CSF), and angiopoietin 1 had good functional out-
come and reduced lesion volume [45]. TGFBR1 (TGF
beta receptor 1), a tan module gene, when mutated in
humans causes the Loeys-Dietz syndrome that is associ-
ated with cerebral aneurysms and arterial dissections
[60]. Moreover, TGF-β1 promotes recovery after experi-
mental ICH [61]. Modulating JAK-STAT signaling also
affects outcomes in experimental ICH [62].
Colony stimulating factor 3 receptor (CSF3R) is a
neutrophil-specific Tan hub gene (Additional file 1: Fig-
ure S14). It encodes the colony stimulating factor 3 re-
ceptor that controls the production, differentiation, and
function of granulocytes/neutrophils, and functions in
cell surface adhesion or recognition processes.
Granulocyte-colony stimulating factor has been investi-
gated as a potential therapeutic target in experimental
ICH and shown to improve recovery from neurological
deficits, reduce edema and BBB permeability, decrease
apoptosis, neutrophil infiltration, and the number of ac-
tivated microglia/macrophages [45]. A mutation in
CSF3R has been implicated in neutrophilic leukemia,
characterized by increased neutrophils, and severe bleed-
ing [63]. Several other tan hub genes are involved in
growth factor signaling pathways such as PIK3CD,
ACTN1, and STAT3. Signal transducer and activator of
transcription 3 (STAT3) (Fig. 7) is involved in ischemic
stroke and intracerebral hemorrhage and has been a
treatment target for experimental ICH [64, 65].
T cell module (magenta module)
T lymphocytes are part of the adaptive immune sys-
tem, and depending upon whether they express CD4
or CD8 surface markers, modulate the immune re-
sponse or elicit cytotoxicity. T lymphocytes have been
detected in perihematomal brain tissue of ICH pa-
tients, and Treg transfer attenuates neurological defi-
cits in experimental ICH [7]. In addition, the
circulating CD4+/CD8+ T lymphocyte ratio has been
suggested as a possible predictor of postoperative
intracranial pressure and short-term prognosis [66].
Regulatory T cells ameliorate BBB damage after cere-
bral ischemia [67] as well as hemorrhagic transform-
ation after tPA administration following ischemic
stroke in part by inhibiting CCL2 (monocyte chemo-
attractant protein 1) and MMP9 [68]. Our previous
study showed differential alternatively spliced tran-
script expression in blood in many T cell receptor
genes [18].
The magenta module was enriched in T cell-specific
genes, including 54 T cell receptor genes (Additional
Table 1 Hub genes in the ICH-significant modules
Green
Yellow Tan Magenta Red Sienna3 Cyan
DarkOlive
Green
ALOX5 ACTN1 ASCC3 LCK AAK1 PUM1 ANK1 DCAF12 ANXA1
ALPL C10orf54 ATIC LRBA AC093838.4 QRICH1 AP2A1 EPB41 ATG3
ANXA3 CHST15 BUB3 MRPS30 AMBRA1 R3HDM1 ASCC2 FAM104A ATG3P1
C19orf59 CSF3R CCDC88C NUP205 CCDC6 RASA3 GUCD1 FAM210B CAPZA1
CASP4 GAB2 CD96 OGFOD1 COG7 RBBP6 MAF1 FAM46C GLRXP3
CDC42EP3 IL17RA CDKAL1 PHF14 CS REPS1 RNF123 GSPT1 MYL12B
CR1 IL6R CHD6 POLH CTB-52I2.4 RNPS1P1 SLC4A1 MKRN1 RP3-452M16.1
CYSTM1 ITPRIP DDX24 PTCD3 CTCF RP11-325E14.2 MKRN4P UBA3
DGAT2 KDM6B DDX47 RASGRP1 CYFIP2 RP5-961K14.1 MKRN5P
DYSF KIAA0247 DIS3L2 RP11-163E9.2 DCAF5 RPRD2 MKRN9P
ETS2 LILRA2 DOCK10 SEPT1 DCAF7 SEC31A MXI1
FCAR LRP10 EPRS SKAP1 DIDO1 SEC61A1 PIP4K2A
FLOT2 MAP3K3 EVL TDP1 ESYT1 SMARCC2 RIOK3
GYG1 MXD1 FNBP4 TRAJ36 GANAB SNRNP200 RP11-329A14.1
KLHL2 NFAM1 FUBP1 TTC3 GORASP2 SOS1 RP11-535M15.2
LIMK2 PIK3CD IARS TTC3P1 INO80D SRRM1 RP4-655L22.4
MAPK14 PREX1 ITK URI1 MED1 SYNRG STRADB
MCTP2 PTPRE KAT6B ZZZ3 MLLT10 TIMM10B STRADBP1
miR3614 RAB3D KRIT1 MTA2 TP53
NLRC4 RASGRP4 MTOR TUBB
NUMB REPS2 NUP210 UBAP2L
PFKFB3 SIRPA NUP62 VPS11
PLBD1 SIRPAP1 PPP2R1A WBP11P1
PYGL SLC12A6 PTBP1
RNF24 SLC6A6
RNU6-196P STAT3
SRPK1 STX3
SULT1B1 ZDHHC18
TRIM25
WDFY3
YIPF1
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Table 2 Selected three relevant hub genes and their relevant functions from each module. N—neutrophil-specific gene,
M—monocyte-specific gene, T—T cell-specific gene, EB—erythroblast-specific genes [43, 45, 48, 54, 63, 64, 71, 73, 74, 81, 84, 91, 92,
94, 102, 107–109, 116–122]
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Fig. 8 Module significant to diagnosis (Dx) and relevant gene ontology (GO) biological processes. Top 3 relevant biological processes presented
in each bar. X-axis: negative Log10-transformed p value for significance with Dx for each significant module. Linear p(Dx)-value displayed in each
bar. Significant over-representation for cell-type specific genes displayed above each module. *GO process, which passes nominal p < 0.05, but
not FDR p < 0.05; the rest pass FDR p < 0.05
Fig. 9 Overlap between differentially expressed genes in peripheral blood (current study) and perihematomal brain tissue [15] between patients
with ICH and controls. There was significant enrichment (p = 6.4 × 10−08) of neutrophil-specific genes in the overlap of 46 genes. The underlined
genes are neutrophil-specific (based on the HeamAtlas [24]). * SATB1 (SATB Homeobox 1)—T cell-specific based on [25]. ** UBE2J1 (ubiquitin
conjugating enzyme E2 J1)—B lymphocyte-specific based on [24]. *** UPP1 (uridine phosphorylase 1)—Monocyte-specific based on [24]. The
green yellow genes ALOX5 (arachidonate 5-lipoxygenase) and PYGL (glycogen phosphorylase L) are hub genes in the greenyellow ICH module.
The red gene AAK1 (AP2 Associated Kinase) is a hub gene in the red ICH module
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file 1: Figure S16) that were involved in T cell activation
and co-stimulation, CD28 signaling in T helper cells,
iCOS-iCOSL signaling in T helper cells, CTLA4 signal-
ing in cytotoxic T lymphocytes, cytotoxic T
lymphocyte-mediated apoptosis of target cells, cytotoxic
T lymphocyte-mediated apoptosis of target cells, Th1
and Th2 pathways. Our previous study showed that dif-
ferential expression of a set of alternatively spliced T cell
genes distinguished ICH from control subjects using a
principal components analysis [18]. Of the 69 T cell re-
ceptor transcripts we previously showed were differen-
tially expressed between ICH and control [18], 58 were
associated with ICH-associated modules in the current
study (44 in magenta, 13 in red, and 1 in tan). This un-
derscores that T cell receptor genes are not only poten-
tial biomarkers, differentially expressed at the gene level
and differentially alternatively spliced at the transcript
level, but are also operating within specific networks that
could affect ICH outcomes.
Additional magenta module molecules included Src
family kinases (SFK). We have shown that pharmaco-
logical inhibition of SFKs improved outcomes and im-
proved BBB function following experimental ICH [69,
70]. Transient inhibition of SFK family member FYN
improved cognitive function after intraventricular
hemorrhage or intraventricular thrombin injection in a
rat model [71]. In our human data, FYN was a magenta
module member (Fig. 5), and one of the magenta hub
genes is a SFK called LCK (LCK proto-oncogene, Src
family tyrosine kinase) (Fig. 5) which is expressed in T
cells [25]. LCK is involved in the selection and matur-
ation of developing T cells and in T cell receptor signal-
ing. Another magenta hub is SKAP1 (Src kinase
associated phosphoprotein 1), which interacts with SFKs.
SKAP1 encodes a T cell adapter protein that promotes
adhesion and degranulation, which stimulates T cell anti-
gen receptors to activate integrins.
Another magenta T cell-specific hub was ITK (IL2 in-
ducible T cell kinase). It is a member of the Tec family
of non-receptor tyrosine kinases, which regulates the de-
velopment, function, and differentiation of T cells and
NKT cells (natural killer T cells). Upon T cell receptor
activation, a series of phosphorylation events recruit ITK
to the cell membrane where it is phosphorylated by
LCK. The gene networks of these three hub genes—ITK
(Additional file 1: Figure S4), LCK (Fig. 5), and SKAP1—
were enriched for T cell receptor signaling and other T
cell pathways.
The magenta hub with the highest intramodular con-
nectivity was IARS (Fig. 3). IARS belongs to the class-I
aminoacyl-tRNA synthetase family which catalyzes the
attachment of an amino acid to its cognate tRNA as part
of the first step of protein synthesis. Besides its enzym-
atic function, aminoacyl-tRNA synthases also function
in homeostasis and signaling pathways, including
mTOR, IFN-γ, and p53 signaling, and have been associ-
ated with cardiovascular disease, autoimmune disorders,
cancers, and neurological disorders [72]. IARS has been
implicated in angiogenesis [73], ischemic injury [74], and
inflammation, and the data here suggests IARS might be
a novel therapeutic target for ICH.
Sphingosine 1-phosphate receptor 1 (S1PR1), a hub in
the magenta module, is connected to 14 genes, notably
all of them hubs: CD96, CDKAL1, DDX24, DDX47,
DOCK10, EVL, IARS, LCK, MRPS30, OGFOD1,
RASGRP1, SEPT1, SKAP1, and TTC3 (Additional file 1:
Figure S3). Fingolimod is an FDA-approved S1PR1 im-
munomodulator treatment for relapsing multiple scler-
osis [7, 75]. Fingolimod treatment reduced cell
infiltration and brain edema while improving neuro-
logical function in experimental ICH [36, 76]. In
addition, it improved outcomes in one small human
ICH trial [77]. Our data suggests that further studies are
warranted not only for S1PR1 but also for its
sub-network of 14 hub genes (Additional file 1: Figure
S3) for their ICH therapeutic potential.
RNA splicing, post-translational and epigenetic
modifications module—red module
The red module was enriched in natural killer (NK)
cell-specific genes, cells for which not much is known
about their function in ICH. The red module was also
enriched for RNA processing, such as regulation of tran-
scription, mRNA splicing via the spliceosome, as well as
epigenetic processes such as chromatin remodeling and
covalent chromatin modifications. Post-translational
modification processes were also represented, including
protein SUMOylation which regulates protein structural
and functional diversity by covalent attachment of a
member of the small ubiquitin-like modifier (SUMO)
family of proteins to lysine residues in specific target
proteins. Our previous work showed extensive differen-
tial alternative splicing in peripheral blood cells follow-
ing human ICH [78], thus indicating the importance of
transcriptional regulation in human ICH, which is likely
immune cell-type specific.
Several red hub genes were involved in regulation of
translation as well, which included mechanistic target of
rapamycin kinase (mTOR) (Additional file 1: Figure S5).
mTOR regulates cellular metabolism, growth, survival,
and autophagy [79] in part by upregulating protein syn-
thesis by phosphorylating key regulators of mRNA trans-
lation and ribosome synthesis [80]. mTOR also regulates
immune responses [81]; controlling the adaptive im-
mune response by promoting differentiation, activation,
and function of T cells, B cells, and antigen-presenting
cells [81]; differentiation and function of regulatory and
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effector T cells [82]; and development and activation of
NK cells [83]. mTOR signaling is activated around the
hematoma within 30 min of experimental ICH, and
returned to baseline by one day [84]. Rapamycin, an
antibiotic that inhibits mTOR, improves behavioral defi-
cits, increases regulatory T cells, increases interleukin-10
and transforming growth factor-β, and reduces
interferon-γ both in peripheral blood and brain follow-
ing experimental ICH [84]. Our data supports a role for
mTOR in human ICH.
Another red module hub gene was a non-coding RNA,
small nuclear ribonucleoprotein U5 subunit 200
(SNRNP200) (Fig. 6). SNRNP200 regulates splicing as
part of the Spliceosome, which is the complex that cata-
lyzes pre-mRNA splicing. It consists of specialized RNA
and small nuclear RNA proteins (snRNPs) U1, U2, U4,
U5, and U6, together with 80 other proteins. U5 snRNP
contains nine specific proteins and SNRNP200 encodes
one of the U5 snRNP-specific proteins. The SNRNP200
network itself contained the hub gene mTOR and 24
out of the 106 genes from the SNRNP200 network were
transcriptional regulators (Fig. 6, highlighted), including
MED1 (hub), MED14, CTCF (hub), MAML2,
SMARCA2, SMARCC1, and SMARCC2 (hub; T cell spe-
cific). MAML2 is a transcriptional coactivator for
NOTCH proteins [85]. Mutations in the Notch signaling
pathway cause heart and vessel disease. Mutations in the
NOTCH1 receptor are associated with cardiac disease,
while mutations in NOTCH3 cause cerebral autosomal
dominant arteriopathy with subcortical infarcts and leu-
koencephalopathy (CADASIL), which is a vascular dis-
order with middle-aged onset, associated with ischemic
stroke and microhemorrhages [85]. Mediator complex
subunit 1 (MED1) and mediator complex subunit 14
(MED14) are components of the mediator complex,
which is a coactivator that regulates transcription of
nearly all RNA polymerase II-dependent genes (tran-
scribing mRNA, most small nuclear RNA and miRNA).
The mediator complex functions as a bridge to con-
vey information from gene-specific regulatory proteins
to the basal RNA polymerase II transcription machin-
ery. SMARCA2, SMARCC1, and SMARCC2 regulate
gene transcription by altering the chromatin structure
around the target genes. Our findings underscore the
importance of transcriptional regulation, alternative
splicing, and epigenetic mechanisms in the patho-
physiology of ICH.
Erythroblast modules—sienna3 and cyan module
The sienna3 and cyan modules were enriched in
erythroblast-specific genes. Erythroblasts are nucleated
red blood cells (NRBC), which are progenitors of the
enucleate erythrocytes in peripheral blood. NRBCs do
not typically cross the barrier between the bone
marrow and the peripheral circulation. They are
found in peripheral blood under conditions that in-
crease erythropoietic pressure such as inflammation,
massive hemorrhage, or severe hypoxia and are asso-
ciated with poor prognosis and higher mortality [86,
87]. Elevated NRBC have been observed in cerebral
hemorrhage in severely growth-restricted infants [88]
and in intraventricular hemorrhage in preterm neo-
nates [89]. NRBC are also observed in some cases of
sudden infant death syndrome [90].
The sienna3 module had 25 erythroblast-specific
genes, including genes involved in congenital hemolytic
anemia (ANK1 (ankyrin 1), EPB42 (erythrocyte mem-
brane protein band 4.2), HK1 (hexokinase 1), SLC4A1
(solute carrier family 4 member 1 (Diego blood group)),
and SPTB (spectrin beta, erythrocytic)), hereditary
spherocytosis (spherical-shaped erythrocytes) (ANK1,
EPB42, SLC4A1, SPTB), anemia (ALAS2 (5′-aminolevu-
linate synthase 2), ANK1, EPB42, HK1, KLF1 (Kruppel
like factor 1), SLC2A1, SLC4A1, SPTB), heme biosyn-
thesis (ALAS2), and heme degradation (BLVRB, biliver-
din reductase B). The cyan module had 24
erythroblast-specific genes, including ones involved in
an iron homeostasis signaling pathway (ABCB10 (ATP
binding cassette subfamily B), FECH (ferrochelatase),
HBQ1 (hemoglobin subunit theta 1), TFRC (transferrin
receptor), and heme biosynthesis (ALAD (aminolevuli-
nate dehydratase), FECH). The expression of
erythroblast-specific genes in peripheral blood suggests
erythroblasts are present in blood of patients with ICH.
Of the sienna3 hub genes, SLC4A1 (Additional file 1:
Figure S11), ANK1 (Additional file 1: Figure S12), and
ring finger protein 123 (RNF123) were erythroblast-
specific. SLC4A1 encodes an anion exchanger expressed
in the erythrocyte plasma membrane. The N-terminal
domain in the cytoplasm is an attachment site for the
red cell skeleton by binding ankyrin. SLC4A1 mutations
cause destabilization of the erythrocyte’s membrane
leading to hereditary spherocytosis. ANK1 attaches inte-
gral membrane proteins to the underlying spectrin-actin
cytoskeleton. ANK1 binds to the erythrocyte membrane
protein band 4.2 (EPB42, present in this module) to
vimentin which is implicated in neuroinflammation [91]
and in cerebral amyloid angiopathy, which is one of the
major causes of ICH [43]. ANK1 also links spectrin beta
chains (encoded by SPTB, also in this module) to the
cytoplasmic domain of SLC4A1 and other exchange
proteins.
Autophagy following ICH
Autophagy involves lysosome-dependent degradation/re-
cycling of cellular components, ranging from proteins to
organelles. In macroautophagy, the components are se-
questered in a double-membrane-bound organelle, the
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autophagosome, to eventually fuse with lysosomes for
digestion by lysosomal hydrolases [92, 93]. The autopha-
gosome is formed by recruitment of about 15
autophagy-related (ATG) proteins and associated pro-
teins. Autophagy plays a fundamental role in homeosta-
sis, cell death, and in the immune/inflammatory
response and its regulation [94]. Dysregulation of au-
tophagy has been implicated in cardiovascular diseases
[95], neurodegenerative diseases [96–99], ischemic
stroke [100], and experimental ICH [101], reviewed in
[102]. Autophagy activation and mitophagy (selective
degradation of mitochondria) promoted by voltage-
dependent anion channels has also been associated with
neuroprotection against cell death following subarach-
noid hemorrhage [103]. Autophagy also occurs following
experimental cerebral ischemia [104] and ICH [101,
102]. Iron overload from the hematoma plays a key role
in ICH-induced autophagy. Infusion of ferrous iron into
rat striatum caused autophagy which was reduced by an
iron chelator [101]. Neuronal cell death following TBI
correlates with autophagy activation and an autophagic
clearance impairment [102].
Autophagy-related biological processes populated sev-
eral of our human ICH modules. The cyan module was
significant for macroautophagy, autophagosome assem-
bly, mitophagy [93] (Fig. 8, Additional file 2: Table S8),
and TORC2 signaling which regulates autophagy [105].
Major autophagy genes in this module included WIPI2,
a component of the autophagosomal machinery that par-
ticipates in the recruitment of certain ATG (autopha-
gy-associated) proteins; ATG9A, which organizes the
pre-autophagosomal structure/phagophore assembly
site; and PTEN-induced putative kinase 1 (PINK1),
which is involved in selective autophagy with rare muta-
tions being associated with Parkinson’s disease [94].
Autophagy, including mitophagy, plays an important
role during erythropoiesis, allowing the proper matur-
ation of red blood cells [106]. The dysfunction of au-
tophagy interferes with the correct erythroid maturation,
leading to hematological abnormalities, such as the re-
lease of immature red blood cells (erythroblasts) from
the bone marrow [106]. In fact, as mentioned above, the
presence of circulating erythroblasts in adults reflects in-
creases in erythropoietic activity or failure of the blood
filtration mechanism during hematopoietic stress such
as inflammation, severe bleeding, hematological malig-
nancy, or severe hypoxia [86].
The cyan module was also enriched in protein ubiqui-
tination pathways which can regulate neuroinflammation
[107] and autophagy [108]. This module was also
enriched for genes in the NRF2-mediated oxidative
stress response pathway, which has been implicated in
enhancing the anti-oxidative capacity, phagocytosis, and
hematoma clearance following experimental ICH by
modulating microglia function following ICH [31].
Clathrin-mediated endocytosis signaling was also
enriched, which is involved in intracellular trafficking
and may link endocytosis to autophagy [109]. Thus, one
might consider the cyan module to be related to
hematoma clearance, since it is associated with autoph-
agy, endocytosis, protein ubiquitination, and oxidative
stress-response pathways.
Another module enriched in autophagy genes was the dar-
kolivegreen module, where regulation of macroautophagy was
the most significant biological process. Moreover, the ATG3
(autophagy related 3) (Additional file 1: Figure S10) hub gene
in this module is a component of the autophagy machinery.
The darkolivegreen module was also enriched for NF-kB sig-
naling that regulates inflammation, notable since there is a bi-
directional regulation between inflammation/NF-kB pathway
and autophagy [110]. Indeed, autophagy may regulate
ICH-induced neuronal damage via NF-kB [111].
Other hub genes in our data that are key players in au-
tophagy or its regulation include WD repeat and FYVE
domain containing 3 (WDFY3, Additional file 1: Figure
S8), mechanistic target of rapamycin kinase (mTOR, Add-
itional file 1: Figure S5), VPS11 (VPS11, CORVET/HOPS
core subunit), and autophagy and beclin 1 regulator 1
(AMBRA1, Additional file 1: Figure S6). Of these, only
mTOR has been shown to play a role in ICH [112]. It is
notable that AMBRA1 is required for adult neurogenesis
[113], which is impaired after experimental ICH [114].
Since autophagy can be a pro-survival or pro-death
mechanism, and may be beneficial or detrimental, more
studies are needed to elucidate its role(s) in human ICH.
Our results point to a role of autophagy in the periph-
eral blood cells and their response to human ICH.
Other blood cell types
Though most modules were enriched in cell
type-specific genes, pathways associated with other cell
types were also represented in these modules. For ex-
ample, the most overrepresented pathway in the neutro-
phil gene-enriched module was B cell receptor signaling.
Though a minor role of B cells in ICH-induced brain in-
jury has been suggested [7], our data suggest B cells are
involved in the pathophysiology of human ICH. B cells,
in addition to producing antibodies, modulate the func-
tions of other immune cells which might be important
in ICH [115].
Blood and brain overlap following human ICH
There was a significant 46-gene overlap from our human
blood study and the genes differentially expressed in hu-
man brain following ICH [15]. The 46 overlapping genes
showed enrichment for neutrophil-specific genes which
may be due to infiltrating neutrophils into perihemato-
mal brain tissue. The 46 genes were involved in
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interleukin 1, 6, 8, and 10 signaling (GNAI3, IL1R1,
IL1RAP, ROCK1, IQGAP1, VASP, MCL1), neuroinflam-
mation signaling (GLS, TLR1, IFNGR1, IL1R1), apop-
tosis (ROCK1, MCL1), PPAR signaling, and leukocyte
extravasation signaling (ROCK1, GNAI3, VASP). In
addition, three of these blood-brain shared genes
(AAK1, ALOX5, and PYGL, Fig. 9) were hub genes in
our data. It is plausible they are master regulators in the
peripheral immune response and potentially play im-
portant role following ICH in perihematomal brain tis-
sue. Thus, they need to be investigated further both in
blood and brain. Treatments targeting the 46 shared
genes might be considered a priority since this presum-
ably would target peripheral blood immune cells, blood
immune cells in brain, and likely brain immune and
non-immune cells.
Limitations
The results need to be validated in a larger study. In
addition, the cell-specific expression of each blood cell
type is based on their expression in healthy subjects and
their cell-specificity may differ in disease. Investigation
of isolated cell types will help delineate the contribution
of each cell type to the immune response to ICH.
Though a given module may be enriched for genes in a
specific cell type, there were always genes from other
cell types associated with those modules. The role of any
given module or hub gene in ICH is difficult to discern
from the current study but can often be inferred from
experimental ICH studies or the literature.
Conclusion
Our data revealed inflammatory, regulatory, and autoph-
agy modules of co-expressed genes associated with ICH
that were highly enriched with cell-specific genes. This
allowed us to identify discrete neutrophil, monocyte, T
cell, natural killer cell, and erythroblast gene modules and
hub genes. Many of the modules and hub genes either
provide novel ICH therapeutic targets or provide human
data supporting animal findings for already existing tar-
gets. The data also revealed a significant overlap between
blood and brain gene responses, underscoring the import-
ance of blood-brain interactions in human ICH.
Additional files
Additional file 1: Figure S1. Soft-thresholding power (A) and connect-
ivity (B). Figure S2. IARS network in the Magenta module. Genes colored
in magenta are hub genes. Figure S3. S1PR1 network within the Ma-
genta module. Genes colored in magenta are hub genes. Note all genes
in the S1PR1’s network are hub genes. Figure S4. ITK network within the
Magenta module. Genes colored in magenta are hub genes. Figure S5.
mTOR Network in the Red Module. Genes colored in red are hub genes.
Figure S6. AMBRA1 Network in the Red Module. Genes colored in red
are hub genes. Figure S7. NLRC4 Network in the GreenYellow Module.
Genes colored in green-yellow are hub genes. Figure S8. WDFY3 Net-
work in the GreenYellow Module. Genes colored in green-yellow are hub
genes. Figure S9. miR3614 Network in the GreenYellow Module. Genes
colored in green-yellow are hub genes. Figure S10. ATG3 Network in the
DarkOliveGreen Module. Genes colored in dark green are hub genes. Fig-
ure S11. SLC4A1 Network in the Sienna3 Module. Genes colored in
brown are hub genes. Figure S12. ANK1 Network in the Sienna3 Module.
Genes colored in brown are hub genes. Figure S13. PIP4K2A Network in
the Cyan Module. Genes colored in cyan are hub genes. Figure S14.
CSF3R Network in the Tan Module. Genes colored in tan are hub genes.
Figure S15. Leukocyte Extravasation Signaling Pathway. Genes circled in
purple are present in the Tan Module. Figure S16. T cell Receptor Signal-
ing Pathway. Genes circled in purple are present in the Magenta Module.
Figure S17. GSK-3β Network in the Tan Module. Genes colored in tan
are hub genes. (PDF 4696 kb)
Additional file 2: Table S1. Subjects' demographic information and
clinical characteristics. Table S2. List of all 21,175 genes and their
respective modules. Table S3. Hypergeometric probability testing for all
p(Dx) < 0.05 modules to all cell-types studied in this document. Table S4.
List of the top 5% of the most interconnected genes (based on intramod-
ular connectivity - kIN) within each module. Green-highlighted genes are
amongst the top 1%. Table S5. IPA canonical pathways for only the hubs
within modules with p(Dx) < 0.05. Pathways in peach color are significant
following Benjamini-Hochberg (B-H) correction. Pathways in tan color -
only following Fisher’s test. Table S6. p-values for each module with re-
spect to diagnosis (A) and time since event (B). Table S7. IPA canonical
pathways for all genes within modules that showed p(Dx) < 0.05. Path-
ways in peach color are significant following Benjamini-Hochberg correc-
tion. Pathways in tan color - only following Fisher’s test. Table S8. DAVID
Gene Ontology results for all modules that showed p(Dx) < 0.05. Path-
ways in peach color are significant following Benjamini-Hochberg correc-
tion. Pathways in tan color - only following Fisher’s test. Table S9. List of
differentially expressed genes (DEGs) and their respective fold-changes
for genes amongst the 21,175 gene list (A). List of hub genes from the
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Carmichael’s study [15] (G). IPA canonical pathways of only the 46 DEGs
that overlapped between this study and Carmichael’s study [15] (H).
(XLSX 756 kb)
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